What is the dose of Kayexalate (sodium polystyrene sulfonate) for hyperkalemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Kayexalate Dosing for Hyperkalemia

The recommended dose of Kayexalate (sodium polystyrene sulfonate) for hyperkalemia is 15-50 g plus sorbitol per oral or per rectum. 1

Adult Dosing

  • Oral administration: 15 g (60 mL) to 60 g (240 mL) of suspension daily, typically given as 15 g (60 mL) one to four times daily 2
  • Rectal administration: 30 g (120 mL) to 50 g (200 mL) every six hours 2

Pediatric Dosing

  • Oral: 1 g/kg up to 15 g (60 mL) every 6 hours as needed 1
  • Rectal: 1 g/kg up to 50 g every 6 hours as needed 1

Administration Guidelines

Oral Administration

  • Administer at least 3 hours before or 3 hours after other oral medications
  • Patients with gastroparesis may require a 6-hour separation 2
  • Administer with patient in upright position
  • May be introduced through a nasogastric tube if necessary

Rectal Administration

  • After initial cleansing enema, insert a large size (French 28) rubber tube into the rectum for about 20 cm
  • Introduce suspension at body temperature by gravity
  • Flush with 50-100 mL of fluid
  • Keep in sigmoid colon for several hours if possible
  • Follow with sodium-free cleansing enema 2

Important Warnings and Precautions

  1. Risk of GI necrosis: Kayexalate, especially when combined with sorbitol, has been associated with intestinal necrosis, which can be fatal 3, 4

  2. Electrolyte disturbances:

    • Contains 1500 mg (65 mEq) of sodium per 60 mL dose 2
    • Can cause hypomagnesemia, hypokalemia, hypocalcemia, and systemic alkalosis 1
  3. Special populations:

    • Neonates: Avoid using commercially available liquid preparation in neonates due to hyperosmolar preservative (sorbitol) content. Hospital pharmacies can prepare sorbitol-free preparations 1
    • Extremely preterm neonates: May develop intestinal hemorrhage (hematochezia) from rectal Kayexalate 1
  4. Efficacy considerations:

    • In-vivo efficiency of sodium-potassium exchange is approximately 33% 2
    • May be less effective than other treatments for hyperkalemia in certain populations 5

Alternative Treatments for Hyperkalemia

For severe hyperkalemia, consider a stepwise approach:

  1. Stabilize myocardial cell membrane:

    • Calcium chloride (10%): 5-10 mL IV over 2-5 minutes, or
    • Calcium gluconate (10%): 15-30 mL IV over 2-5 minutes
  2. Shift potassium into cells:

    • Sodium bicarbonate: 50 mEq IV over 5 minutes
    • Glucose plus insulin: 25 g glucose and 10 U regular insulin IV over 15-30 minutes
    • Nebulized albuterol: 10-20 mg over 15 minutes
  3. Promote potassium excretion:

    • Diuresis: furosemide 40-80 mg IV
    • Kayexalate: 15-50 g plus sorbitol PO or PR
    • Dialysis (for severe cases) 1

Efficacy Evidence

A randomized clinical trial demonstrated that sodium polystyrene sulfonate (30 g daily for 7 days) was superior to placebo in reducing serum potassium levels in patients with mild hyperkalemia and CKD (mean difference between groups: -1.04 mEq/L) 6.

However, newer potassium binders may offer advantages over Kayexalate, including faster onset of action, better selectivity for potassium, and potentially improved safety profiles 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.